InMode Ltd. (NASDAQ:INMD) Shares Sold by Boston Trust Walden Corp

Boston Trust Walden Corp cut its position in InMode Ltd. (NASDAQ:INMD) by 2.4% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 1,408,071 shares of the healthcare company’s stock after selling 34,962 shares during the quarter. Boston Trust Walden Corp owned about 1.68% of InMode worth $23,867,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in the business. Tributary Capital Management LLC bought a new stake in InMode during the first quarter worth approximately $65,000. Allspring Global Investments Holdings LLC raised its holdings in InMode by 9.9% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 7,645 shares of the healthcare company’s stock worth $165,000 after acquiring an additional 691 shares during the period. Wasatch Advisors LP increased its stake in shares of InMode by 46.6% in the first quarter. Wasatch Advisors LP now owns 327,046 shares of the healthcare company’s stock worth $7,067,000 after purchasing an additional 103,946 shares during the period. Principal Financial Group Inc. acquired a new position in shares of InMode during the first quarter worth approximately $1,853,000. Finally, Commonwealth Equity Services LLC raised its stake in InMode by 7.6% during the 1st quarter. Commonwealth Equity Services LLC now owns 75,784 shares of the healthcare company’s stock valued at $1,638,000 after purchasing an additional 5,385 shares during the last quarter. Institutional investors own 68.04% of the company’s stock.

InMode Trading Down 0.8 %

NASDAQ INMD opened at $17.55 on Friday. InMode Ltd. has a 12 month low of $14.87 and a 12 month high of $26.80. The stock has a 50 day moving average of $16.48 and a 200-day moving average of $17.37. The company has a market cap of $1.47 billion, a PE ratio of 10.09 and a beta of 2.17.

InMode (NASDAQ:INMD) last announced its quarterly earnings results on Thursday, August 1st. The healthcare company reported $0.34 EPS for the quarter, missing analysts’ consensus estimates of $0.38 by ($0.04). The firm had revenue of $102.60 million during the quarter, compared to analyst estimates of $104.81 million. InMode had a net margin of 35.81% and a return on equity of 21.00%. The business’s revenue was down 24.6% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.65 EPS. As a group, sell-side analysts predict that InMode Ltd. will post 1.58 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts recently commented on INMD shares. Needham & Company LLC reaffirmed a “hold” rating on shares of InMode in a research report on Thursday, October 10th. BTIG Research initiated coverage on InMode in a report on Thursday, October 17th. They issued a “buy” rating and a $25.00 target price on the stock. Barclays reduced their price target on shares of InMode from $29.00 to $27.00 and set an “overweight” rating on the stock in a research report on Monday, October 14th. Jefferies Financial Group lowered InMode from a “buy” rating to a “hold” rating and decreased their price objective for the company from $21.00 to $19.00 in a research report on Tuesday, July 23rd. Finally, Canaccord Genuity Group lowered their price target on shares of InMode from $21.00 to $16.00 and set a “hold” rating for the company in a research report on Friday, July 12th. Four research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to MarketBeat, InMode has a consensus rating of “Hold” and an average price target of $22.60.

InMode Company Profile

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures.